A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

Trial Profile

A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms A-PREDICT
  • Most Recent Events

    • 16 Nov 2016 Status changed from recruiting to completed.
    • 15 Nov 2016 Last checked against European Clinical Trials Database record.
    • 16 Oct 2015 Accrual to date is 53% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top